[ Bioelectronic Wound Care ]

Chronic infected
wounds
meet the
innovative fields
.

A calibrated magnetic field developed to disrupt bacterial biofilm, so that established antiseptics and antibiotics can act where biofilm blocks them today. Preclinical, in vitro. Scroll to rotate the system.

Quality management system ISO 13485, TÜV SÜD

Diabetic Foot Ulcers: a growing global crisis

Chronic wound care is one of the most expensive, least solved problems in modern medicine, and it is accelerating.

589M*
Adults (20-79 years) living with diabetes globally
~10K €*
Average annual DFU care cost per patient
+45%*
Projected diabetes increase by 2050

* Source: IDF Global Diabetes Atlas

Why current treatments fall short

  • Typical antiseptics cannot reach the deep wound pockets or biofilms where bacteria hide.
  • Rising antimicrobial resistance is rendering standard antibiotic regimens progressively less effective.
  • Existing procedures are painful, costly, and dressing-intensive, driving low adherence and recurring readmissions.

The breakthrough

The field reaches where topical antiseptics cannot.

In vitro, it disrupts the biofilm and the bacterial cell wall, so antimicrobials can act again.

A bioelectronic platform that potentiates established antimicrobials

The Azyro system is a modular, magnetic-field-driven application platform, engineered for hospitals and outpatient care.

Azyro, bioelectronic wound care

Advanced mechanism

Precisely controlled magnetic fields disrupt bacterial cell walls and biofilm in vitro. The intended effect is to let established antiseptics act where biofilm blocks them today.

  • Patient comfort.Contact-free application through the dressing.
  • Modular design.Future adaptation to different body regions, under development.
  • Hospital + home care.Lightweight and portable, usable across the full continuum of care.
  • Seamless integration.Fits existing clinical care plans, no new SOPs to learn.
  • Deep-tissue reach.Targets the bacteria living in pockets where topicals never arrive.
  • Synergistic, not substitutive.The field is used together with the antimicrobial already in place. In vitro and in vivo, the combination remained effective at concentrations even below the MIC.
EP2025/068630 and EP4400155ISO 13485 quality management system (TÜV SÜD)

Explore the diabetic foot ulcer device

Research collaborations

  • 01
    Azyro S.A.Luxembourg
  • 02
    University Medicine GreifswaldGermany
  • 03
    Wroclaw Medical UniversityPoland
  • 04
    Wiener NeustadtAustria

Join us, and be part of our journey

Azyro develops magnetic-field technology for chronic infected wounds. Our goal is to reduce the infection-driven complications that lead to amputation. We are looking for clinical, distribution and investment partners to get there.